共 50 条
Osteosarcoma in Children 5 Years of Age or Younger at Initial Diagnosis
被引:22
|作者:
Worch, Jennifer
Matthay, Katherine K.
Neuhaus, John
Goldsby, Robert
DuBois, Steven G.
[1
]
机构:
[1] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA
关键词:
osteosarcoma;
outcome;
SEER;
treatment;
young children;
OSTEOGENIC-SARCOMA;
PROGNOSTIC-FACTORS;
CHEMOTHERAPY;
METHOTREXATE;
PHARMACOKINETICS;
MANAGEMENT;
EXTREMITY;
CANCER;
D O I:
10.1002/pbc.22509
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background. Since osteosarcoma is extremely rare in children <= 5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients. Procedure. Patients <20 years of age with high-grade osteosarcoma reported to national SEER database from 1973 to 2006 were separated into two groups based on age at diagnosis: <= 5 years (n = 49) and 6-19 years (n = 1,687). Patient, tumor, and treatment characteristics were compared using Fisher exact tests. Overall survival was estimated by Kaplan-Meier methods and compared using log-rank tests and Cox models. Results. Patients <= 5 years had higher proportions of osteosarcoma arising from the upper limb compared to older patients (24.5% vs. 11.2%; P = 0.006). These very young patients had a significantly higher proportion of telangiectatic histology (10.2% vs. 2.9%; P=0.017). Sex, metastatic status, race, or ethnicity did not differ by age. A higher proportion of very young patients was treated with amputation (55.2% vs. 27.3%; P = 0.002). Five-year overall survival was inferior for patients with localized osteosarcoma 5 years of age or younger compared to older children (51.9% vs. 67.3%; P = 0.03). After controlling for metastatic status, year of diagnosis, and tumor site, the hazard ratio for death in very young patients was 1.6 (95% confidence interval 1.02-2.36; P = 0.04) compared to older patients. Conclusions. Tumor characteristics, treatment, and outcomes differ among children <= 5 years of age compared to older pediatric patients. These differences may reflect differences in tumor biology. Pediatr Blood Cancer 2010;55:285-289. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:285 / 289
页数:5
相关论文